Disease Control Achieved Using Atezolizumab + Bevacizumab in a Patient With Sarcomatoid Hepatocellular Carcinoma (SHCC), a Rare Variant Excluded From the IMbrave150 Trial

• Κύριοι συγγραφείς: Maria G. Fencer MD (Συγγραφέας), Catherine H. Davis MD, MPH (Συγγραφέας), Jieqi Liu MD (Συγγραφέας), Mark A. Galan MD (Συγγραφέας), Kristen R. Spencer DO, MPH (Συγγραφέας)
• Μορφή: Βιβλίο
• Έκδοση: SAGE Publishing, 2022-12-01T00:00:00Z.
• Θέματα: article
• Διαθέσιμο Online: Connect to this object online.

Sarcomatoid hepatocellular carcinoma (SHCC) is a rare variant of liver cancer that lacks treatment options. The IMbrave trail demonstrated the efficacy of atezolizumab and bevacizumab (A + B) in patients with unresectable hepatocellular carcinoma but excluded patients with sarcomatoid variants. Here...